Associated Papers
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants.
Han CW et al.
Cancers, 2020
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Goodwin J et al.
Nature Communications, 2017
28548087 (PubMed )
Supplement: ncomms15503-s1.pdf
EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features.
Jia X et al.
Contemporary Oncology (poznan, Poland), 2015
Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y et al.
International Journal of Clinical and Experimental Pathology, 2013
Select a paper to view details